

Aztreonam**Section**

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Cefiderocol**Section**

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

IndicationsCarbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Klebsiella pneumoniae*Carbapenem resistant *Escherichia coli***Ceftaroline****Section**

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime + avibactam**Section**

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

IndicationsCarbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant Enterobacterales

Carbapenem resistant *Klebsiella pneumoniae*Carbapenem resistant *Escherichia coli*

Ceftolozane + tazobactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Colistin (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant *Enterobacterales*

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Daptomycin

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

Eravacycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Other carbapenem resistant *Enterobacterales*

Fifth generation cephalosporins

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Fosfomycin (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant *Enterobacterales*

Imipenem + cilastatin + relebactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

Other specified other antibiotic resistant *Enterobacterales*

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant *Enterobacterales*

Linezolid

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Meropenem + vaborbactam

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant *Acinetobacter baumannii*

Other carbapenem resistant *Enterobacterales*

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Omadacycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Oxazolidinones

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Plazomicin

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Other carbapenem resistant *Enterobacterales*

Carbapenem resistant *Escherichia coli*

Carbapenem resistant *Klebsiella pneumoniae*

Polymyxin B (injection)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant *Acinetobacter baumannii*

Other carbapenem resistant *Enterobacterales*

Carbapenem resistant *Klebsiella pneumoniae*

Carbapenem resistant *Escherichia coli*

Polymyxins

Section

Reserve group antibiotics

- .

Indications

Other specified bacterial diseases

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to [linezolid](#) for

Vancomycin resistant *Enterococcus*

Tigecycline

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases